FDA Extends Conflict Disclosure Policy To All Advisory Panel Members
This article was originally published in The Tan Sheet
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members
You may also be interested in...
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies
Recognizing that planning and conducting advisory committee meetings can be "traumatic" for both government and industry, FDA is taking steps to improve the process, said Charles Ganley, the head of the agency's OTC drugs program